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ABSTRACT  
Objective: The main purpose of this study was to develop a simple, precise, rapid and accurate method for the simultaneous quantification of 
verapamil and enalapril in the present of enalaprilat in human plasma. 
Methods: Analytes were extracted from plasma using a protein precipitation extraction method. Chromatography was achieved on Discovery C18, 
50 × 2.1 mm, 5 μm column. Samples were chromatographed in a gradient mode (eluent A (acetonitrile–water–formic acid, 5: 95: 0.1 v/v), eluent B 
(acetonitrile–formic acid, 100: 0.1 v/v)). The initial content of the eluent B is 0%, which increases linearly by 1.0 min to 100% and to 1.01 min 
returns to the initial 0%. The mobile phase was delivered at a flow rate of 0.400 ml/min into the mass spectrometer ESI chamber. The sample 
volume was 5 μl.  
Results: The total chromatographic run time was 2.0 min and the elution of verapamil, enalapril, enalaprilat and IS (bisoprolol) occurred at ~1.09, 
1.03, 0.96 and 1.01 min, respectively. A linear response function was established at 1-100 ng/ml for verapamil hydrochloride, 2-200 ng/ml for 
enalapril maleate, 1-100 ng/ml for enalaprilat dehydrate in human plasma. The % accuracy of LLOQ samples prepared with the different biological 
matrix lots were found 99.2 % for enalapril, 103.4 % for enalaprilat, 90.6 % for verapamil, which were found within the range of 80.00-120.00% for 
the seven different plasma lots. % CV for LLOQ samples was observed as 4.9%, 5.9 %, 9.0 % respectively, which are within 20.00% of the acceptance 
criteria. The % mean recovery for enalapril in LQC, MQC and HQC was 103.6 %, 100.1 % and 102.4 %, for enalaprilat in LQC, MQC and HQC was 
103.2 %, 98.0 % and 101.1 %, for verapamil in LQC, MQC and HQC was 97.9 %, 96.1 % and 98.6 % respectively. 
Conclusion: A new rapid method was developed for simultaneous determination of verapamil and enalapril in the present of enalaprilat in human 
plasma. The method was strictly validated according to the ICH guidelines. Acquired results demonstrate that proposed strategy can be effortlessly 
and advantageously applied for routine examination of verapamil and enalapril in the present of enalaprilat in human plasma.  
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Bioanalytical methods for appraising drugs and their metabolites in 
biological samples play an important role in calculating and 
interpreting data from the studies on bioavailability, bioequivalence, 
and pharmacokinetics. 
Verapamil hydrochloride is a first generation calcium channel blocker 
used for treatment of hypertension, angina pectoris and 
supraventricular tachyarrhythmias. Verapamil has been linked to a low 
rate of serum enzyme elevations during therapy and to rare instances of 
clinically apparent acute liver injury. The chemical name of verapamil is 
2-(3,4-dimethoxyphenyl)-5-[2-(3,4-dimethoxyphenyl)ethyl-methyl-
amino] -2-propan-2-ylpentanenitrile (fig. 1) [1]. 
Enalapril maleate is chemically described as (2S)-1-[(2S)-2-[[(1S)-1-
(ethoxycarbonyl)-3-phenylpropyl] amino] propanoyl] pyrrolidine-2-
carboxylic acid (Z)-butenedioate (fig. 2). Enalapril maleate is a 
prodrug which metabolized rapidly in the liver to ethyl ester of a 
long-acting enalaprilat (fig. 3) which inhibits angiotensin-converting 
enzyme (ACE) in human subjects and animals [2, 3]. 
 
 
Fig. 1: Chemical structure of verapamil hydrochloride 
 
Fig. 2: Chemical structure of enalapril maleate 
 
 
Fig. 3: Chemical structure of enalaprilat 
 
In the contemporary literature, few bioanalytical methods were 
reported for quantification of verapamil and enalapril in the present 
of enalaprilat in human plasma [4-6]. Therefore, it was thought 
desirable to develop a simple, accurate, cheap and fast procedure 
that could be applied for the simultaneous determination of 
verapamil and enalapril in the present of enalaprilat in human 
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plasma, this study performed assay validations as per guidelines [7]. 
While this method with validation details were economical and 
applied for pharmacokinetic studies of verapamil and enalapril. 
MATERIALS AND METHODS  
Chemicals and reagents  
Verapamil (purity 100.0 %), enalapril (purity 99.3 %), enalaprilat 
(purity 100.0 %), bisoprolol (Internal Standard) (purity 99.9 %) 
were purchased from Moehs Catalana, S. L., Spain, Zhejiang Huahai 
Pharmaceutical Co., Ltd, КНР, EDQM–Council of Europe. HPLC 
grade acetonitrile and methanol were purchased from 
CHROMASOLV, HPLC grade formic acid were purchased from 
Fluka. All other chemicals and reagents were of analytical grade. 
Microcaps® disposable micropipettes (50 μl, catalog number: 1-
000-0500) were purchased from Drummond Scientific Company, 
USA. The control human dipotassium ethylenediaminetetraacetic 
acid (K2EDTA) plasma sample was procured from Red Cross 
Society, Ukraine.  
Instrumentation and chromatographic conditions  
A Shimadzu HT (Shimadzu, Japan) LC system equipped with 
degasser (DGU-14A), binary pump (LC-20ADXR) along with auto-
sampler (SIL-20ACXR) was used to inject 5 μl aliquots of the 
processed samples on Discovery C18, 50 × 2.1 mm, 5 μm column 
maintained at 25±1 °C. Samples were chromatographed in a gradient 
mode (eluent A (acetonitrile–water–formic acid, 5: 95: 0.1 v/v), 
eluent B (acetonitrile–formic acid, 100: 0.1 v/v)). The initial content 
of the eluent B is 0%, which increases linearly by 1.0 min to 100% 
and to 1.01 min returns to the initial 0%. The mobile phase was 
delivered at a flow rate of 0.400 ml/min into the mass spectrometer 
ESI chamber. Paramatrs of electrospray ionizer and MRM parametrs 
are listed in table 1-2. The analytical data were processed by Analyst 
Software (version 1.5.2). 
  
Table 1: Parameters of ionizer electrospray 
S. No. Parametr Value 
1 Polarity Positive 
2 Nebulizer Gas (NEB, Gas 1) 15 
3 Curtain Gas (CUR) 8 
4 Collision Gas (CAD) 4 
5 IonSpray Voltage (IS) 5000 
6 Temperature (TEM) 400 
7 Turbo IonSpray Gas 8 
8 Horizontal Position 5.3 
9 Lateral Position 1.3 
 
Table 2: Multiple reaction monitoring (MRM) parameters 
ID Parent, m/z Daughter, m/z Time, ms DP, V FP, V EP, V CE, V CXP, V 
Enalapril 377.397 234.3 50 41 210 11 29 20 
Enalaprilat 349.328 206.3 50 46 220 11 27 34 
Bisoprolol (IS) 326.435 116.3 50 46 260 11 27 20 
Verapamil  455.385 165.4 50 61 320 11 39 28 
*Abbreviations: DP, declustering potential; FP, focusing potential; EP, entrance potential; CE, collision energy; CXP, collision cell exit potential 
 
Standard solutions  
Verapamil, enalapril, enalaprilat and IS were weighed accurately 
into volumetric flasks using an analytical microbalance. 
Approximately 1 mg/ml primary stock solutions of enalaprill, 0.5 
mg/ml primary stock solutions of enalaprilat, 0.25 mg/ml primary 
stock solutions of bisoprolol (IS) and 0.5 mg/ml primary stock 
solutions of verapamil solutions were prepared in methanol. The 
stock solutions were stored at −20 °C, which were found to be 
stable for 1 mo. The stock solutions of verapamil, enalapril, 
enalaprilat were successively diluted with methanol and water to 
prepare secondary stocks and working solutions. Secondary stock 
solutions and working solutions were used to prepare calibration 
curve (CC) and quality control (QC) samples. Working stock 
solutions were stored at 4 °C for a week. Working stocks were 
used to prepare plasma calibration standards. A working IS 
solution (20 ng/ml) was prepared in acetonitrile: methanol (50:50 
v/v). Blank human plasma was screened before spiking to ensure 
that it was free from endogenous interference at retention times of 
verapamil, enalapril, enalaprilat and IS, respectively. Calibration 
standards’ samples (1-100 ng/ml for verapamil hydrochloride, 2-
200 ng/ml for enalapril maleate, 1-100 ng/ml for enalaprilat 
dehydrate) were prepared by spiking the blank human K2EDTA 
plasma with appropriate concentration of verapamil, enalapril and 
enalaprilat.  
Samples for the determination of precision and accuracy were 
prepared by spiking control human plasma in bulk with verapamil, 
enalapril and enalaprilat at appropriate concentrations (for 
verapamil hydrochloride 3.0 ng/ml low QC [LQC], 30.0 ng/ml 
medium QC [MQC], and 75.0 ng/ml high QC [HQC], for enalapril 
maleate 6.0 ng/ml low QC [LQC], 60.0 ng/ml medium QC [MQC], and 
150.0 ng/ml high QC [HQC], for enalaprilat dihydrate 3.0 ng/ml low 
QC [LQC], 30.0 ng/ml medium QC [MQC], and 75.0 ng/ml high QC 
[HQC],) and 120 μL plasma aliquots were distributed into different 
tubes. All the samples were stored at −80 °C±10 °C.  
Sample preparation  
A simple protein precipitation extraction method was followed for 
extraction of verapamil, enalapril, enalaprilat at from human 
plasma. From the deep freezer, the required quantities of CC 
standards and QC samples were withdrawn. The samples were 
thawed at room temperature. To an aliquot of 100 μl plasma, 20 μl 
of IS was added. To this mixture, 300 μl of acetonitrile: methanol 
(50:50 v/v) was added and vortexed for 2 min, followed by 
centrifugation at 6000 rpm for 5 min at 4 °C. After centrifugation, 
approximately 50 μl supernatant was aliquoted into, respectively, 
labeled autosampler vials, which were later placed in the 
autosampler at 15 °C±4 °C. 10 μl of the sample was injected onto 
LC-MS/MS system for analysis. 
Method validation 
A full validation according to the ICH guidelines was performed for 
the assay in K2EDTA human plasma. 
Specificity and selectivity 
The specificity of the method was evaluated by analyzing human 
plasma samples from different lots to investigate the potential 
interferences at the chromatographic peak region for analytes and 
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IS. The acceptance criterion for the experiment was that should 
have<20% area response to that of the LLOQ level response in the 
same matrix. Two lots of hemolyzed plasma samples were also 
analyzed to ensure specificity against potential biological 
interferences. 
Linearity  
The points CC (1-100 ng/ml for verapamil hydrochloride, 2-200 
ng/ml for enalapril maleate, 1-100 ng/ml for enalaprilat dehydrate) 
were constructed by plotting the peak area ratio of each analyte: IS 
against the nominal concentration of calibration standards in 
K2EDTA human plasma. Following the evaluation of different 
weighing factors, the results were fit into linear regression analysis 
using 1/X2 (X: Concentration) weighing factor. The CC should have a 
correlation coefficient (r) of 0.99 or better. The acceptance criteria 
for each back-calculated standard concentration were±15% 
deviation from the nominal value except at LLOQ, which was set 
at±20%. 
Recovery 
The efficiency of verapamil, enalapril, enalaprilat and IS extraction 
from human plasma was determined by comparing the responses of 
the analytes extracted from replicate QC samples (n=6) with those of 
neat standard solutions spiked in post-extracted plasma blank 
sample at equivalent concentrations by protein precipitation 
extraction method. Recovery of enalapril was determined at LQC 
(6.28 ng/ml) and HQC (150.00 ng/ml) concentrations, enalaprilat 
was determined at LQC (2.99 ng/ml) and HQC (75.8 ng/ml) 
concentrations, verapamil was determined at LQC (2.99 ng/ml) and 
HQC (75.8 ng/ml) concentrations whereas the recovery of IS was 
determined at a single concentration of 20 ng/ml. 
Matrix effect 
The effect of human plasma constituents over the ionization of 
verapamil, enalapril, enalaprilat, and IS was determined by post-
column infusion method to evaluate matrix effect. Briefly, an 
infusion pump delivers a constant amount of analyte into LC system 
outlet entering to mass spectrometer inlet. To follow the analyte 
signal, the mass spectrometer was operated in MRM mode. The 
human plasma constituent sample extract was injected on LC 
column. A steady ion response was obtained as a function of time 
since the analyte was infused at a constant rate. Any endogenous 
compound that elutes from the column which causes a variation in 
ESI response of the infused analyte was seen as a suppression or 
enhancement in the response of the infused analyte. A separate 
experiment was performed with verapamil, enalapril, enalapril, and 
IS solutions, which were infused at a constant rate, and blank matrix 
sample injected through the LC. To evaluate matrix effect, different 
lots of human plasma were spiked with analyte concentration levels 
at LQC and HQC levels. According to guidelines, the acceptance 
criterion for each back-calculated concentration was±15% deviation 
from the nominal value. 
Precision and accuracy 
The intra-assay precision and accuracy were estimated by analyzing 
six replicates containing verapamil, enalapril, enalapril, at four 
different QC levels concentrations (for verapamil hydrochloride 3.0 
ng/ml low QC [LQC], 30.0 ng/ml medium QC [MQC], and 75.0 ng/ml 
high QC [HQC], for enalapril maleate 6.0 ng/ml low QC [LQC], 60.0 
ng/ml medium QC [MQC], and 150.0 ng/ml high QC [HQC], for 
enalaprilat dihydrate 3.0 ng/ml low QC [LQC], 30.0 ng/ml medium 
QC [MQC], and 75.0 ng/ml high QC [HQC]) in human plasma. The 
four-level QC samples on four different runs were performed to 
assess the interassay precision. The acceptance criteria for each 
back-calculated standard concentration were 85-115% accuracy 
from the nominal value except at LLOQ, which was set at 80-120%. 
Stability experiments 
Stability tests were conducted to evaluate the stability of verapamil, 
enalapril, enalaprilat in plasma samples under different conditions. 8 
h bench top stability, processed samples stability (autosampler 
stability for 26 h at 10 °C), three cycles of freeze-thaw stability, 30 d 
of long-term stability at −80±10 °C were performed at LQC and HQC 
levels using six replicates at each level. Samples were considered 
stable if assay values’ acceptance criterion was of accuracy (i.e., 85-
115% from fresh samples) and precision (i.e.,±15% relative 
standard deviation [RSD]). 
RESULTS AND DISCUSSION 
In previous study, a rapid, sensitive, and highly selective liquid 
chromatography-tandem mass spectrometry method was developed 
and validated for simultaneous determination of enalapril and its 
major active metabolite enalaprilat in human plasma. The analytes 
were extracted from plasma samples by liquid-liquid extraction, 
separated on a Zorbax Extend-C18 column, and detected by tandem 
mass spectrometry with a Turbo IonSpray ionization interface. The 
method has a lower limit of quantification (LLOQ) of 0.1 ng/ml for 
both enalapril and enalaprilat. The chromatographic run time was 
3.5 min [8]. 
In the present study, optimization and critical evaluation of mobile 
phase composition (gradient), flow rate, and analytical column were 
important to obtain good resolution of peaks of interest from the 
endogenous components, which in turn affect reproducibility and 
sensitivity of the method. Selection of chromatographic conditions 
for the proposed method was optimized to suit the preclinical 
pharmacokinetic studies. To ease the sample preparation in 
microtubes and to reduce the usage of solvent, the plasma volume 
was kept low. Initial feasibility experiments of a various mixture(s) 
of solvents such as acetonitrile, methanol and formic acid along with 
altered flow rates (in the range of 0.1-0.6 ml/min) were performed 
to optimize an effective chromatographic resolution of verapamil, 
enalapril, enalaprilat, and IS. Various analytical columns were tested 
to obtained good and reproducible response within short run time. 
The resolution of peaks was best achieved with Discovery C18, 50 × 
2.1 mm, 5 μm column. Samples were chromatographed in a gradient 
mode (eluent A (acetonitrile–water–formic acid, 5: 95: 0.1 v/v), 
eluent B (acetonitrile–formic acid, 100: 0.1 v/v)). The initial content 
of the eluent B is 0%, which increases linearly by 1.0 min to 100% 
and to 1.01 min returns to the initial 0%. The mobile phase was 
delivered at a flow rate of 0.400 ml/min into the mass spectrometer 
ESI chamber. The injection volume was 5 μl.  
The purpose of sample extraction optimization is mainly to achieve 
high extraction recovery with negligible or low matrix effects to 
improve sensitivity and reliability of LC-MS/MS analysis [9-16]. A 
poor extraction procedure decreases method robustness due to the 
presence of endogenous interference in the sample extracts, which 
are not efficiently cleaned up due to poor extraction procedure 
decreases the method robustness due to the endogenous 
interference in the sample extracts. With time-saving advantage and 
simplicity, the protein precipitation extraction method was chosen 
as an extraction method. The attained LLOQ was sufficient to 
quantify verapamil, enalapril, enalaprilat in low-dose pharmaco-
kinetic studies. 
Verapamil, enalapril, enalaprilat eluted at ~1.09, 1.03 and 0.96 min, 
respectively. During a direct infusion experiment, the mass spectra 
for verapamil, enalapril, enalaprilat and IS revealed peaks at m/z 
455.385, 377.397, 349.328 and 326.435, respectively as protonated 
molecular ions, [M+H]+. Typical multiple reaction monitoring 
chromatograms of verapamil, enalapril, enalaprilat and internal 
standard in dipotassium ethylenediaminetetraacetic acid human 
blank plasmaare shown in fig. 4-5. 
The total chromatographic run time was 2.0 min and the elution of 
verapamil, enalapril, enalaprilat and IS (bisoprolol) occurred at 
~1.09, 1.03, 0.96 and 1.01 min, respectively.  
Specificity 
Different lots of plasma were analysed to ensure that no 
endogenous interferences were present at the retention time of 
verapamil, enalapril, enalaprilat. LLOQ level samples along with 
plasma blank from the respective plasma lots were prepared and 
analysed (table 3). 
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Fig. 4: Typical multiple reaction monitoring chromatograms of verapamil (right up panel), enalapril (left up panel), enalaprilat (left down 
panel) and internal standard (right down panel) in dipotassium ethylenediaminetetraacetic acid human blank plasma 
 
 
Fig. 5: Typical multiple reaction monitoring chromatograms of verapamil (right up panel), enalapril (left up panel), enalaprilat (left down 
panel) and internal standard (right down panel) in dipotassium ethylenediaminetetraacetic acid human blank plasma 
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Table 3: Results of specificity for verapamil, enalapril, enalaprilat 
S. No. Enalapril Enalaprilat Verapamil 
STD BL LLOQ % Interference STD BL LLOQ % Interference STD BL LLOQ % Interference 
Area RT Area RT Area RT 
1 0 1958 1.03 NIL 0 353 0.97 NIL 0 892 1.09 NIL 
2 0 1831 1.03 NIL 0 322 0.96 NIL 0 817 1.09 NIL 
3 0 1692 1.03 NIL 0 358 0.97 NIL 0 926 1.09 NIL 
4 0 1888 1.03 NIL 0 372 0.97 NIL 0 978 1.08 NIL 
5 0 1914 1.03 NIL 0 409 0.96 NIL 0 1024 1.09 NIL 
6 0 1745 1.04 NIL 0 379 0.98 NIL 0 896 1.09 NIL 
7 0 1902 1.03 NIL 0 382 0.96 NIL 0 902 1.08 NIL 
8 0 1806 1.03 NIL 0 379 0.97 NIL 0 865 1.09 NIL 
9 0 1896 1.03 NIL 0 348 0.97 NIL 0 910 1.09 NIL 
10 0 1807 1.03 NIL 0 347 0.97 NIL 0 896 1.09 NIL 
*Average of triplicate injections, In all plasma blanks, the response at the retention time of verapamil, enalapril, enalaprilat was less than 20% of 
LLOQ response and at the retention time of IS, the response was less than 5% of mean IS response in LLOQ.  
 
Linearity 
The calibration standard curves had a reliable reproducibility over 
the standard concentrations across the calibration range. The 
average regression (n=3) was found to be>0.997 for all analytes. 
The calibration curve (fig. 6) (peak area ratio Vs Concentration) was 
linear over working range for enalapril maleate of 2 to 200.00 ng/ml 
with 7 point calibration used for quantification by linear regression, 
shown in fig. 6. The regression equation for the analysis was. 
Y=0.0187x+0.000248 with coefficient of correction (r2) = 0.9993.
  
 
Fig. 6: The calibration curve of enalapril maleate in human plasma 
 
The calibration curve (fig. 7) (peak area ratio Vs Concentration) was 
linear over working range for enalaprilat dihydrate of 1 to 100.00 ng/ml 
with 7 point calibration used for quantification by linear regression, 
shown in fig. 7. The regression equation for the analysis was. 
Y=0.00833x+0.00133 with coefficient of correction (r2) = 0.9995. 
The calibration curve (fig. 8) (peak area ratio Vs Concentration) was 
linear over working range for verapamil hydrochloride of 1 to 100.00 
ng/ml with 7 point calibration used for quantification by linear 
regression, shown in fig. 8. The regression equation for the analysis was 
Y=0.0162x+0.00391 with coefficient of correction (r2) = 0.9992. 
Recovery 
The % mean recovery for enalapril, enalaprilat and verapamil in 
LQC, MQC and HQC are listed in tables 4-6. 
 
Table 4: The % mean recovery of enalapril for LQC, MQC and HQC 
S. No. LQC MQC HQC 
1 6.06 61.5 152 
2 6.02 62.6 158 
3 6.74 55.7 155 
4 6.27 59.2 155 
5 6.00 61.2 147 
Mean 6.22 60.0 154 
SD 0.309 2.72 4.01 
% CV 5.0 4.5 2.6 
% Mean Recovery 103.6 100.1 102.4 
*Abbreviations: Lower quality control (LQC), middle quality control (MQC), higher quality control (HQC), Each value is represented as a mean±SD 
of 5 observations (n=5), SD: Standard Deviation, RSD: Relative Standard Deviation, #Acceptance criteria<2.0. 
Lin AP EpVp 051017.rdb (Ep): "Linear" Regression ("1 / x" weighting): y = 0.0187 x + 0.000248 (r = 0.9993)
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Fig. 7: The calibration curve of enalaprilat dihydrate in human plasma 
 
 
Fig. 8: The calibration curve of verapamil hydrochloride in human plasma 
 
Table 5: The % mean recovery of enalaprilat for LQC, MQC and HQC 
S. No. LQC MQC HQC 
1 3.49 30.6 76.8 
2 2.96 29.8 77.2 
3 3.30 26.7 72.8 
4 2.94 29.2 78.3 
5 2.80 30.7 73.9 
Mean 3.10 29.4 75.8 
SD 0.288 1.61 2.35 
% CV 9.3 5.5 3.1 
% Mean Recovery 103.2 98.0  101.1 
*Abbreviations: Lower quality control (LQC), middle quality control (MQC), higher quality control (HQC), Each value is represented as a mean±SD 
of 5 observations (n=5), SD: Standard Deviation, RSD: Relative Standard Deviation, #Acceptance criteria<2.0. 
Lin AP EpVp 051017.rdb (Et): "Linear" Regression ("1 / x" weighting): y = 0.00833 x + -0.00133 (r = 0.9995)
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Lin AP EpVp 051017.rdb (Vp): "Linear" Regression ("1 / x" weighting): y = 0.0162 x + 0.00391 (r = 0.9992)
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Table 6: The % mean recovery of verapamil for LQC, MQC and HQC 
S. No. LQC MQC HQC 
1 3.10 28.5 73.3 
2 2.92 30.8 76.2 
3 2.90 27.4 74.9 
4 3.01 28.3 72.0 
5 2.76 29.2 73.3 
Mean 2.94 28.8 73.9 
SD 0.127 1.27 1.65 
% CV 4.3 4.4 2.2 
% Mean Recovery 97.9 96.1 98.6 
*Abbreviations: Lower quality control (LQC), middle quality control (MQC), higher quality control (HQC), Each value is represented as a mean±SD 
of 5 observations (n=5), SD: Standard Deviation, RSD: Relative Standard Deviation, #Acceptance criteria<2.0. 
 
The % mean recovery for enalapril in LQC, MQC and HQC was 103.6 
%, 100.1 % and 102.4 %, for enalaprilat in LQC, MQC and HQC was 
103.2 %, 98.0 % and 101.1 %, for verapamil in LQC, MQC and HQC 
was 97.9 %, 96.1 % and 98.6 % respectively. 
Intraday (within run) and Inter-day (between run) precision 
and accuracy 
The within-run coefficients of variation ranged between 0.336 % and 
0.617 % for verapamil. The within-run percentages of nominal 
concentrations ranged between 98.82 % and 100.62 % for verapamil. 
The between-run coefficients of variation ranged between 0.334 % and 
0.612 % for verapamil. The between-run percentages of nominal 
concentrations ranged between 98.97 % and 101.76 % for verapamil. 
Results are presented in table 7. The assay values on both the occasions 
(intra-and inter-day) were found to be within the accepted limits. 
The within-run coefficients of variation ranged between 0.351 % 
and 0.717 % for enalapril. The within-run percentages of nominal 
concentrations ranged between 99.13 % and 101.11 % for enalapril. 
The between-run coefficients of variation ranged between 0.343 % 
and 0.671 % for enalapril. The between-run percentages of nominal 
concentrations ranged between 99.17 % and 101.76 % for enalapril. 
Results are presented in table 8. 
The within-run coefficients of variation ranged between 0.321 % 
and 0.541 % for enalaprilat. The within-run percentages of nominal 
concentrations ranged between 99.13 % and 101.12 % for 
enalaprilat. The between-run coefficients of variation ranged 
between 0.314 % and 0.663 % for enalaprilat. The between-run 
percentages of nominal concentrations ranged between 99.17 % and 
101.03 % for enalaprilat. Results are presented in table 9. 
 
Table 7: Intra-day and Inter-day precision data of verapamil 
Day Intra-day precision Inter-day precision 
 Mean R. S. D. % Mean R. S. D. % 
1 98.82 0.378 101.76 0.334 
2 100.41 0.617 98.97 0.390 
3 100.62 0.336 100.53 0.612 
*Each value is represented as a mean±SD of observations, SD: Standard Deviation, RSD: Relative Standard Deviation, #Acceptance criteria<2.0 
 
Table 8: Intra-day and Inter-day precision data of enalapril 
Day Intra-day precision Inter-day precision 
Mean R. S. D.% Mean R. S. D.% 
1 99.13 0.351 101.76 0.514 
2 101.11 0.717 99.17 0.343 
3 100.82 0.376 100.13 0.671 
*Each value is represented as a mean±SD of observations, SD: Standard Deviation, RSD: Relative Standard Deviation, #Acceptance criteria<2.0 
 
Table 9: Intra-day and Inter-day precision data of enalaprilat 
Day Intra-day precision Inter-day precision 
 Mean R. S. D. % Mean R. S. D. % 
1 99.13 0.321 100.77 0.314 
2 100.31 0.541 99.17 0.490 
3 101.12 0.396 101.03 0.663 
*Each value is represented as a mean±SD of observations, SD: Standard Deviation, RSD: Relative Standard Deviation, #Acceptance criteria<2.0 
 
Matrix effect 
The lowest concentration with the RSD<20% was taken as LLOQ 
and was found to be 1.98 ng/ml for enalapril, 1.03 ng/ml for 
enalaprilat, 0.91 ng/ml for verapamil. The % accuracy of LLOQ 
samples prepared with the different biological matrix lots were 
found 99.2 % for enalapril, 103.4 % for enalaprilat, 90.6 % for 
verapamil, which were found within the range of 80.00-120.00% 
for the seven different plasma lots. % CV for LLOQ samples was 
observed as 4.9%, 5.9 %, 9.0 % respectively, which are within 
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Table 10: Results of matrix effect of enalapril 








% CV 4.9 
% Mean Recovery 99.2 
*Abbreviations: Lower limit of quantification (LLOQ), Each value is represented as a mean±SD of 5 observations (n=5), SD: Standard Deviation, 
RSD: Relative Standard Deviation, #Acceptance criteria<2.0. 
 
Table 11: Results of matrix effect of enalaprilat 








% CV 5.9 
% Mean Recovery 103.4 
*Abbreviations: Lower limit of quantification (LLOQ), Each value is represented as a mean±SD of 5 observations (n=5), SD: Standard Deviation, 
RSD: Relative Standard Deviation, #Acceptance criteria<2.0. 
 
Table 12: Results of matrix effect of verapamil 








% CV 9.0 
% Mean Recovery 90.6 
*Abbreviations: Lower limit of quantification (LLOQ), Each value is represented as a mean±SD of 5 observations (n=5), SD: Standard Deviation, 
RSD: Relative Standard Deviation, #Acceptance criteria<2.0. 
 
Table 13: Stability data of bisoprolol, enalapril, enalapril at QCs in human plasma 
Nominal concentration (ng/ml) Stability Stability data 
mean±SD °(n=6) Accuracy (%)• Precision (% CV) 
Verapamil-2.99 0 h 2.98±0.41 99.6 2.29 
7 h (bench-Top) 2.98±0.33 99.6 2.36 
22 h (in-injector) 2.98±0.37 99.6 2.40 
3 FT cycles 2.97±0.45 99.33 2.33 
Enalapril–6.28 0 h 6.27±0.37 99.8 3.08 
7 h (bench-Top) 6.27±0.22 99.8 2.51 
22 h (in-injector) 6.26±0.42 99.6 3.16 
3 FT cycles 6.26±0.37 99.6 2.16 
Enalaprilat–2.99 0 h 2.98±0.38 99.6 3.12 
7 h (bench-Top) 2.98±0.45 99.6 3.07 
22 h (in-injector) 2.97±0.67 99.3 3.43 
3 FT cycles 2.96±0.44 98.9 3.11 
Verapamil-75.8 0 h 75.5±0.43 99.6 2.07 
7 h (bench-Top) 75.5±0.53 99.6 3.34 
22 h (in-injector) 75.4±0.47 99.5 2.32 
3 FT cycles 75.5±0.51 99.5 3.01 
Enalapril–150.0 0 h 149.9±0.51 99.9 3.15 
7 h (bench-Top) 149.7±0.31 99.8 2.32 
22 h (in-injector) 149.6±0.22 99.7 2.02 
3 FT cycles 149.2±0.64 99.4 3.24 
Enalaprilat–75.8 0 h 75.5±0.53 99.6 3.08 
7 h (bench-Top) 75.3±0.27 99.3 2.04 
22 h (in-injector) 75.3±0.38 99.3 2.54 
3 FT cycles 75.1±0.57 99.0 2.84 
 °Back-calculated plasma concentrations; •Mean assayed concentration/mean assayed concentration at 0 h × 100. FT: Freeze-thaw, SD: Standard 
deviation, QC: Quality control, The results were found to be within the assay variability limits during the entire process. 
Logoyda  




The predicted concentrations for verapamil (2.99 ng/ml and 75.8 
ng/ml), enalapril (6.28 ng/ml and 150.0 ng/ml), enalaprilat (2.99 
ng/ml and 75.8 ng/ml) deviated within±15% of the fresh sample 
concentrations in a battery of stability tests namely, in-injector (22 
h), bench-top (7 h), and repeated four freeze/thaw cycles stability 
(table 13). 
CONCLUSION 
In summary, a highly sensitive, specific, reproducible, rapid and 
high-throughput LC-MS/MS assay was developed and validated to 
quantify verapamil and enalapril in the present of enalaprilat in 
human plasma as per the regulatory guidelines. The present method 
involved a simple precipitation method of sample preparation, 
which gave consistent and reproducible recoveries. Acquired results 
demonstrate that proposed strategy can be effortlessly and 
advantageously applied for routine examination of verapamil and 
enalapril in the present of enalaprilat in human plasma. Hence, the 
combination was taken up for developing a bioanalytical method 
development and validation so that further it would be useful for 
performing pharmacokinetic studies. 
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